Tuberculosis vaccines: Barriers and prospects on the quest for a transformative tool

Immunological Reviews

Volumn 264, Issue 1, 2015, Pages 363-381

  Karp, Christopher L ^a   Wilson, Christopher B ^a   Stuart, Lynda M ^a,b  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Immunopathogenesis; Mycobacterium tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; SUBUNIT VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CORRELATIONAL STUDY; DRUG EFFICACY; GENE DELETION; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; INFECTION PREVENTION; INFECTION RISK; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER T CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT RISK; POPULATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE; TUBERCULOSIS; VIRUS TRANSMISSION; WHOLE CELL; ANIMAL; DISEASE MODEL; IMMUNOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 84923172363     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12270     Document Type: Article

References (185)

1. Maxwell JC. Review of "A treatise in the kinetic theory of gases" by Henry William Watson. Nature 1877;18:242-246.
2. Russell DG. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev 2011;240:252-268.
3. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012;54:784-791.
4. Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008;122:1043-1051; quiz 1052-1043.
5. de Beaucoudrey L, et al. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010;89:381-402.
6. Sologuren I, et al. Partial recessive IFN-gammaR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet 2011;20:1509-1523.
7. Browne SK, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012;367:725-734.
8. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001;19:93-129.
9. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993;178:2249-2254.
10. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993;178:2243-2247.
11. WHO/UNAIDS. Global HIV/AIDS Response. Epidemic Update and Health Sector Progress Towards Universal Access. Progress report, 2011.
12. Geldmacher C, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008;198:1590-1598.
13. Dixon WG, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376.
14. Koike T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011;70:2148-2151.
15. Flynn JL, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-572.
16. Gonzalez-Juarrero M, et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol 2005;77:914-922.
17. Mayer-Barber KD, et al. Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 2010;184:3326-3330.
18. Saunders BM, Briscoe H, Britton WJ. T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin Exp Immunol 2004;137:279-287.
19. Andersen P, Woodworth JS. Tuberculosis vaccines-rethinking the current paradigm. Trends Immunol 2014;35:387-395.
20. Mittrucker HW, et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci USA 2007;104:12434-12439.
21. Goldsack L, Kirman JR. Half-truths and selective memory: interferon gamma, CD4(+) T cells and protective memory against tuberculosis. Tuberculosis 2007;87:465-473.
22. Kagina BM, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010;182:1073-1079.
23. Tameris MD, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-1028.
24. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008;177:1164-1170.
25. Doherty TM, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002;40:704-706.
26. Higuchi K, Harada N, Fukazawa K, Mori T. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis 2008;88:244-248.
27. Skerry C, Harper J, Klunk M, Bishai WR, Jain SK. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS ONE 2012;7:e39680.
28. Subbian S, et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 2011;7:e1002262.
29. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003;1:17-24.
30. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science 2012;335:936-941.
31. Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. In search of a new paradigm for protective immunity to TB. Nat Rev Microbiol 2014;12:289-299.
32. Barry CE 3rd, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7:845-855.
33. Lin PL, et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 2013;57:4237-4244.
34. Lin PL, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 2014;20:75-79.
35. Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science 2010;328:852-856.
36. Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-977.
37. Bloom CI, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE 2013;8:e70630.
38. Lesho E, et al. Transcriptional responses of host peripheral blood cells to tuberculosis infection. Tuberculosis 2011;91:390-399.
39. Lu C, et al. Novel biomarkers distinguishing active tuberculosis from latent infection identified by gene expression profile of peripheral blood mononuclear cells. PLoS ONE 2011;6:e24290.
40. Maertzdorf J, et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 2011;6:e26938.
41. Maertzdorf J, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 2012;109:7853-7858.
42. Bloom CI, et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS ONE 2012;7:e46191.
43. Dorhoi A, et al. Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur J Immunol 2014;44:2380-2393.
44. Mayer-Barber KD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014;511:99-103.
45. Redford PS, et al. Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J Infect Dis 2014;209:270-274.
46. McNab FW, et al. Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-gamma for production of IL-12 and bacterial killing in mycobacterium tuberculosis-infected macrophages. J Immunol 2014;193:3600-3612.
47. Byrnes AA, et al. Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy. J Leukoc Biol 2008;84:1447-1453.
48. Hyrcza MD, et al. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J Virol 2007;81:3477-3486.
49. Willis MD, Winston CA, Heilig CM, Cain KP, Walter ND, Mac Kenzie WR. Seasonality of tuberculosis in the United States, 1993-2008. Clin Infect Dis 2012;54:1553-1560.
50. Evans TG. Update on TB vaccines-2014, 2014.
51. Comas I, et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet 2013;45:1176-1182.
52. Comas I, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010;42:498-503.
53. Copin R, et al. Sequence diversity in the pe_pgrs genes of Mycobacterium tuberculosis is independent of human T cell recognition. MBio 2014;5:e00960-00913.
54. Gagneux S. Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci 2012;367:850-859.
55. Huang CC, et al. The effect of HIV-related immunosuppression on the risk of tuberculosis transmission to household contacts. Clin Infect Dis 2014;58:765-774.
56. Shah M, Kasambira TS, Adrian PV, Madhi SA, Martinson NA, Dorman SE. Longitudinal analysis of QuantiFERON-TB Gold In-Tube in children with adult household tuberculosis contact in South Africa: a prospective cohort study. PLoS ONE 2011;6:e26787.
57. Dharmadhikari AS, et al. Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis 2011;91:329-338.
58. Barreto ML, et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial. Vaccine 2011;29:4875-4877.
59. BasuRoy R, et al. Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med 2012;186:378-384.
60. Chan PC, et al. Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. Thorax 2013;68:263-268.
61. Eisenhut M, et al. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine 2009;27:6116-6120.
62. Roy A, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 2014;349:g4643.
63. Soysal A, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005;366:1443-1451.
64. Poulsen A. Some clinical features of tuberculosis. 1. Incubation period. Acta Tuberc Scand 1950;24:311-346.
65. Wallgren A. The time-table of tuberculosis. Tubercle 1948;29:245-251.
66. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 2002;70:4501-4509.
67. Reiley WW, et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci USA 2008;105:10961-10966.
68. Wolf AJ, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008;205:105-115.
69. Khader SA, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-377.
70. Cooper AM, Callahan JE, Keen M, Belisle JT, Orme IM. Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. Tuber Lung Dis 1997;78:67-73.
71. Jung YJ, Ryan L, LaCourse R, North RJ. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2005;201:1915-1924.
72. Karp CL. Unstressing intemperate models: how cold stress undermines mouse modeling. J Exp Med 2012;209:1069-1074.
73. Lin PL, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012;122:303-314.
74. Keele BF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105:7552-7557.
75. Mills CC, O'Grady F, Riley RL. Tuberculin conversion in the "naturally infected" guinea pig. Bull Johns Hopkins Hosp 1960;106:36-45.
76. Riley RL, et al. Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am J Epidemiol 1995;142:3-14.
77. Abel L, El-Baghdadi J, Bousfiha AA, Casanova JL, Schurr E. Human genetics of tuberculosis: a long and winding road. Philos Trans R Soc Lond B Biol Sci 2014;369:20130428.
78. Cobat A, et al. Tuberculin skin test negativity is under tight genetic control of chromosomal region 11p14-15 in settings with different tuberculosis endemicities. J Infect Dis 2014;doi: 10.1093/infdis/jiu446 (Online published).
79. Hawn TR, Matheson AI, Maley SN, Vandal O. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol Mol Biol Rev 2013;77:608-627.
80. Spring M, Polhemus M, Ockenhouse C. Controlled human malaria infection. J Infect Dis 2014;209(Suppl 2):S40-S45.
81. Porter CK, et al. A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). Vaccine 2011;29:5869-5885.
82. Lyons AG. The human dengue challenge experience at the Walter Reed Army Institute of Research. J Infect Dis 2014;209(Suppl 2):S49-S55.
83. Seder RA, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013;341:1359-1365.
84. Minassian AM, Satti I, Poulton ID, Meyer J, Hill AV, McShane H. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis 2012;205:1035-1042.
85. Rosenthal SR, McEnery JT, Raisys N. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J Asthma Res 1968;5:309-323.
86. Kim JH, et al. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci USA 2013;110:19095-19100.
87. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: ASM Press, 1994:531-557.
88. Dye C. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered. J R Soc Interface 2013;10:20130365.
89. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367:1173-1180.
90. Colditz GA, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702.
91. Mangtani P, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014;58:470-480.
92. Aronson NE, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004;291:2086-2091.
93. Rodrigues LC, Mangtani P, Abubakar I. How does the level of BCG vaccine protection against tuberculosis fall over time? BMJ 2011;343:d5974.
94. Behr MA, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284:1520-1523.
95. Favorov M, et al. Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guerin (BCG) vaccines from different sources, Kazakhstan. PLoS ONE 2012;7:e32567.
96. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA. A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 2008;76:5200-5214.
97. Poyntz HC, Stylianou E, Griffiths KL, Marsay L, Checkley AM, McShane H. Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis. Tuberculosis 2014;94:226-237.
98. Beverley PC, Sridhar S, Lalvani A, Tchilian EZ. Harnessing local and systemic immunity for vaccines against tuberculosis. Mucosal Immunol 2014;7:20-26.
99. Kaufmann SH. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010;33:567-577.
100. Calmette A, Guerin C, Boquet A, Negre L. La vaccination preventive contre la tuberculose par le "BCG". Paris: Masson, 1927.
101. Calmette A. Sur la vaccination preventive des enfants nouveau-nes contre la tuberculose par le BCG. Annales de l'Institute Pasteur 1927;41:201-232.
102. Meeting of the strategic advisory group of experts on immunization, April 2014 - conclusions and recommendations. Wkly Epidemiol Rec 2014;89:221-236.
103. Blanden RV, Lefford MJ, Mackaness GB. The host response to Calmette-Guerin bacillus infection in mice. J Exp Med 1969;129:1079-1107.
104. Werner GT. The effect of BCG-vaccination on vaccinia virus infections in mice. Experientia 1979;35:1514-1515.
105. Ota MO, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002;168:919-925.
106. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007;61:299-305.
107. Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between viruses. Immunol Rev 2010;235:244-266.
108. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011;9:355-361.
109. Cheng SC, et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014;345:1250684.
110. Kleinnijenhuis J, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012;109:17537-17542.
111. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity 2013;38:373-383.
112. da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP. Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol 2014;5:152.
113. Kaufmann SH, et al. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines 2014;13:619-630.
114. Arbues A, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013;31:4867-4873.
115. Sacks DL. Vaccines against tropical parasitic diseases: a persisting answer to a persisting problem. Nat Immunol 2014;15:403-405.
116. von Reyn CF, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010;24:675-685.
117. Nell AS, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS ONE 2014;9:e89612.
118. Rodgers JR, Cook RG. MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol 2005;5:459-471.
119. Heinzel AS, et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J Exp Med 2002;196:1473-1481.
120. Joosten SA, et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog 2010;6:e1000782.
121. Cohen GB, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661-671.
122. Lewinsohn DA, et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 2007;3:1240-1249.
123. Lewinsohn DM, et al. Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol 2001;166:439-446.
124. Lindestam Arlehamn CS, Lewinsohn D, Sette A, Lewinsohn D. Antigens for CD4 and CD8 T cells in tuberculosis. Cold Spring Harb Perspect Med 2014;4:a018465.
125. Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH. Innovative strategies to identify M. tuberculosis antigens and epitopes using genome-wide analyses. Front Immunol 2014;5:256.
126. Hoppes R, Ekkebus R, Schumacher TN, Ovaa H. Technologies for MHC class I immunoproteomics. J Proteomics 2010;73:1945-1953.
127. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol 2011;12:485-491.
128. Shane HL, Klonowski KD. Every breath you take: the impact of environment on resident memory CD8 T cells in the lung. Front Immunol 2014;5:320.
129. Hansen SG, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473:523-527.
130. Mackay LK, et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012;109:7037-7042.
131. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012;491:463-467.
132. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998;11:514-532.
133. Teitelbaum R, et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA 1998;95:15688-15693.
134. Dinadayala P, Sambou T, Daffe M, Lemassu A. Comparative structural analyses of the alpha-glucan and glycogen from Mycobacterium bovis. Glycobiology 2008;18:502-508.
135. Sani M, et al. Direct visualization by cryo-EM of the mycobacterial capsular layer: a labile structure containing ESX-1-secreted proteins. PLoS Pathog 2010;6:e1000794.
136. Yang L, Sinha T, Carlson TK, Keiser TL, Torrelles JB, Schlesinger LS. Changes in the major cell envelope components of Mycobacterium tuberculosis during in vitro growth. Glycobiology 2013;23:926-934.
137. Born WK, Reardon CL, O'Brien RL. The function of gammadelta T cells in innate immunity. Curr Opin Immunol 2006;18:31-38.
138. Modlin RL, et al. Lymphocytes bearing antigen-specific gamma delta T-cell receptors accumulate in human infectious disease lesions. Nature 1989;339:544-548.
139. Zheng J, Liu Y, Lau YL, Tu W. gammadelta-T cells: an unpolished sword in human anti-infection immunity. Cell Mol Immunol 2013;10:50-57.
140. Hata S, et al. Extensive junctional diversity of rearranged human T cell receptor delta genes. Science 1988;240:1541-1544.
141. Hoft DF, Brown RM, Roodman ST. Bacille Calmette-Guerin vaccination enhances human gamma delta T cell responsiveness to mycobacteria suggestive of a memory-like phenotype. J Immunol 1998;161:1045-1054.
142. Lafaille JJ, DeCloux A, Bonneville M, Takagaki Y, Tonegawa S. Junctional sequences of T cell receptor gamma delta genes: implications for gamma delta T cell lineages and for a novel intermediate of V-(D)-J joining. Cell 1989;59:859-870.
143. Kabelitz D, Bender A, Prospero T, Wesselborg S, Janssen O, Pechhold K. The primary response of human gamma/delta + T cells to Mycobacterium tuberculosis is restricted to V gamma 9-bearing cells. J Exp Med 1991;173:1331-1338.
144. D'Souza CD, Cooper AM, Frank AA, Mazzaccaro RJ, Bloom BR, Orme IM. An anti-inflammatory role for gamma delta T lymphocytes in acquired immunity to Mycobacterium tuberculosis. J Immunol 1997;158:1217-1221.
145. Vavassori S, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nat Immunol 2013;14:908-916.
146. Spencer CT, Abate G, Blazevic A, Hoft DF. Only a subset of phosphoantigen-responsive gamma9delta2 T cells mediate protective tuberculosis immunity. J Immunol 2008;181:4471-4484.
147. Li B, et al. Disease-specific changes in gammadelta T cell repertoire and function in patients with pulmonary tuberculosis. J Immunol 1996;157:4222-4229.
148. Shen Y, et al. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 2002;295:2255-2258.
149. Dieli F, et al. Vgamma9/Vdelta2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur J Immunol 2000;30:1512-1519.
150. El Daker S, et al. An abnormal phenotype of lung Vgamma9Vdelta2 T cells impairs their responsiveness in tuberculosis patients. Cell Immunol 2013;282:106-112.
151. Pinheiro MB, et al. CD4-CD8-alphabeta and gammadelta T cells display inflammatory and regulatory potentials during human tuberculosis. PLoS ONE 2012;7:e50923.
152. Chen CY, et al. Phosphoantigen/IL2 expansion and differentiation of Vgamma2Vdelta2 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog 2013;9:e1003501.
153. Birkinshaw RW, Kjer-Nielsen L, Eckle SB, McCluskey J, Rossjohn J. MAITs, MR1 and vitamin B metabolites. Curr Opin Immunol 2014;26:7-13.
154. Kjer-Nielsen L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012;491:717-723.
155. Huang S, et al. MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. Proc Natl Acad Sci USA 2009;106:8290-8295.
156. Dusseaux M, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011;117:1250-1259.
157. Le Bourhis L, Guerri L, Dusseaux M, Martin E, Soudais C, Lantz O. Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol 2011;32:212-218.
158. Le Bourhis L, et al. MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog 2013;9:e1003681.
159. Eckle SB, et al. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J Exp Med 2014;211:1585-1600.
160. Gold MC, et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J Exp Med 2014;211:1601-1610.
161. Gold MC, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 2010;8:e1000407.
162. Harriff MJ, et al. Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8(+) T cells. PLoS ONE 2014;9:e97515.
163. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-890.
164. Montamat-Sicotte DJ, et al. A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. J Clin Invest 2011;121:2493-2503.
165. Torrelles JB, et al. Structural differences in lipomannans from pathogenic and nonpathogenic mycobacteria that impact CD1b-restricted T cell responses. J Biol Chem 2011;286:35438-35446.
166. Dascher CC, et al. Conservation of a CD1 multigene family in the guinea pig. J Immunol 1999;163:5478-5488.
167. Hiromatsu K, et al. Characterization of guinea-pig group 1 CD1 proteins. Immunology 2002;106:159-172.
168. Dascher CC, et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int Immunol 2003;15:915-925.
169. Seshadri C, Turner MT, Lewinsohn DM, Moody DB, Van Rhijn I. Lipoproteins are major targets of the polyclonal human T cell response to Mycobacterium tuberculosis. J Immunol 2013;190:278-284.
170. Kasmar AG, et al. CD1b tetramers bind alphabeta T cell receptors to identify a mycobacterial glycolipid-reactive T cell repertoire in humans. J Exp Med 2011;208:1741-1747.
171. Van Rhijn I, et al. A conserved human T cell population targets mycobacterial antigens presented by CD1b. Nat Immunol 2013;14:706-713.
172. Kronenberg M, Zajonc DM. A 'GEM' of a cell. Nat Immunol 2013;14:694-695.
173. Van Rhijn I, et al. TCR bias and affinity define two compartments of the CD1b-glycolipid-specific T Cell repertoire. J Immunol 2014;192:4054-4060.
174. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-568.
175. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 2007;5:405-417.
176. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog 2008;4:e1000239.
177. Rothchild AC, Jayaraman P, Nunes-Alves C, Behar SM. iNKT cell production of GM-CSF controls Mycobacterium tuberculosis. PLoS Pathog 2014;10:e1003805.
178. Sada-Ovalle I, Skold M, Tian T, Besra GS, Behar SM. Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit Care Med 2010;182:841-847.
179. Shimizu K, et al. KLRG+ invariant natural killer T cells are long-lived effectors. Proc Natl Acad Sci USA 2014;111:12474-12479.
180. Subbian S, et al. Spontaneous latency in a rabbit model of pulmonary tuberculosis. Am J Pathol 2012;181:1711-1724.
181. Bacchetti P, Deeks SG, McCune JM. Breaking free of sample size dogma to perform innovative translational research. Sci Transl Med 2011;3:87ps24.
182. Corey L, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011;3:79ps13.
183. Middelkoop K, et al. Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study. BMC Infect Dis 2011;11:156.
184. Marx FM, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis 2014;58:1676-1683.
185. Wood R, Bekker LG. Isoniazid preventive therapy for tuberculosis in South Africa: an assessment of the local evidence base. S Afr Med J 2014;104:174-177.